EMBARK Trial Videos

Discussion Between Expert Clinicians and Patients on the EMBARK Trial, A Journal Club for Patients with Prostate Cancer - Matthew Cooperberg Details Matthew Cooperberg, alongside patient advocates Stan Rosenfeld, Bruce Zweig, Nathan Roundy, and Leszek Izdebski, engages in a comprehensive Q&A session with Neal Shore, Stephen Freedland, and Rana McKay. They explore the potential applications of enzalutamide for low-risk prostate cancer patients on active surveillance, referencing findings from the ENACT and EMBARK trials. Dr. Shore emphasizes th...
EMBARK Trial: Enzalutamide Monotherapy & Combination Therapy for High-Risk Prostate Cancer - Stephen Freedland, Neal Shore, & Rana McKay Details Matthew Cooperberg is joined by Steve Freedland, Neal Shore, and Rana McKay to discuss the findings from the EMBARK trial, a landmark study examining treatments for prostate cancer patients experiencing biochemical recurrence. The EMBARK trial compares traditional androgen deprivation therapy (ADT) using leuprolide alone, with the addition of enzalutamide, and enzalutamide alone. Drs. Freedland an...
The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore Details Zach Klaassen and Neal Shore discuss the outcomes of the EMBARK trial, focusing on treatment strategies for high-risk biochemically recurrent prostate cancer. In this detailed conversation, Dr. Shore explains the trial’s structure, which tested the efficacy of enzalutamide combined with leuprolide acetate or as monotherapy. Trial findings reveal a significant improvement in metastasis-free surviva...
Advancing Prostate Cancer Care: The EMBARK Study and Implications for Clinical Practice - Stephen Freedland Details Daniel George and Stephen Freedland delve into the EMBARK study, a trial on Enzalutamide for high-risk non-metastatic biochemical recurrence of prostate cancer. They explore the approach of using Enzalutamide, both in combination with Leuprolide and as monotherapy, highlighting its significant impact on metastasis-free survival. The study reveals that combination therapy substantially reduces the...
Guideline Revisions Seek to Optimize Detection and Management of Recurrent Prostate Cancer Without Evident Metastasis, Journal Club - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen discuss the amended AUA guidelines on advanced prostate cancer, focusing on biochemically recurrent prostate cancer without metastasis after local treatment. The guidelines emphasize informing patients about the risk of developing metastatic disease and recommend serial PSA measurements and clinical evaluations. High-risk patients, identified by pathologic grade or...
Parsing the Evidence from the EMBARK Trial on a Promising New Drug Regimen in High-Risk Non-Metastatic Hormone-Sensitive Prostate Cancer - Matthew Cooperberg Details Zach Klaassen converses with Matthew Cooperberg about findings from the EMBARK study, presented at ESMO and published in the New England Journal. The study focuses on the efficacy of enzalutamide (enza) plus leuprolide versus leuprolide alone in treating high-risk non-metastatic hormone-sensitive prostate cancer. Dr. Cooperberg notes the predictability of better efficacy with combination treatment...
PSMA PET's Influence on Prostate Cancer Studies - Jeremie Calais Details Phillip Koo talks with Jeremie Calais about the EMBARK trial and the impact of PSMA PET on patient population characterization. The discussion explores how the EMBARK trial began back in 2015 before the existence of PSMA PET and how its introduction has affected the understanding and definition of patient populations in prostate cancer studies. Calais explains how their team retrospectively looked...
Interpreting EMBARK Trial Results: Intensified Treatment and Hormone Therapy in High-Risk Patients - Christian Gratzke Details Zach Klaassen hosts a high-level discussion with Christian Gratzke about the potential practice-changing outcomes of the EMBARK trial, specifically the impressive results of intensified treatment in high-risk patients. Dr. Gratzke suggests that intermittent hormone treatment could also be effective. The conversation also touches on enzalutamide monotherapy as a standalone treatment and how its suc...
EMBARK Trial Shows Promising Results for High-Risk Prostate Cancer Treatment, Enzalutamide's Impact on Metastasis-Free Survival - Neal Shore Details Neal Shore discusses the EMBARK trial with Alicia Morgans. The study investigated whether enzalutamide plus leuprolide treatment or enzalutamide monotherapy could prolong metastasis-free survival compared with placebo plus leuprolide for men with high-risk biochemical relapse. The study's primary endpoint was met, with patients in the combination arm showing a 58% reduction in the risk of metastas...
The EMBARK Study: A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Thera... Details Stephen Freedland presents the manuscript entitled A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Therapy: EMBARK Study Design. The objective of EMBARK was to value the efficacy and safety of enzalutamide in combination with leuprolide acetate or monotherapy compared wi...

EMBARK Trial Videos

Login